|
Dr. Ivan Lieberburg is currently Executive Vice President, Chief Medical Officer at Elan Company,
plc (formerly Athena Neurosciences, Inc.), a worldwide biopharmaceutical company listed on the New York Stock Exchange, where he has held a number of positions over the last 18 years, most recently Senior Vice President of Research.
Prior to joining Elan in 1987, Dr. Lieberburg held faculty positions at Albert Einstein School of Medicine and Mt. Sinai School of Medicine. Dr. Lieberburg received an A.B. in Biology from Cornell University, a Ph.D. in Neurobiology from The Rockefeller University, and an M.D. from the University of Miami School of Medicine. He performed his postdoctoral research at The Rockefeller University and his medical residency and postdoctoral fellowship at the University of California, San Francisco, where he is presently a Clinical Professor of Medicine.
Dr. Lieberburg has authored over 100 scientific publications, and has been named to a number of honors including Rockefeller University Fellow, Public Health Corps Scholar, National Research Service Award, Hartford Foundation Scholar, and McKnight Fellow. He is board-certified in internal medicine
and endocrinology/metabolism. Dr. Lieberburg is a director of Neuromolecular Pharmaceuticals, and
he sits on the scientific advisory boards of Health Care Ventures, Flagship Ventures, NewcoGen, Neuromolecular Pharmaceuticals, CovX, Hythiam, and the Keystone Symposium. | 